Diligent Acquires Insightia, a Leading SaaS Provider of Critical Insights and Analytics
11.1.2022 16:00:00 EET | Business Wire | Press release
Diligent, the global leader in modern governance providing SaaS solutions across governance, risk, compliance and ESG, today announced that it has acquired Insightia, a leading SaaS provider of expert insights and intelligent analytics for listed companies, with a focus on shareholder activism, proxy voting and corporate governance. Financial terms of the transaction were not disclosed.
Formed from the 2020 merger of Activist Insight and Proxy Insight, Insightia offers a single source of global public company information to a range of global investment banks, law firms, proxy solicitors, and other corporate advisors. Representative clients include PJT CamberView, Glass Lewis, Morrow Sodali, FTI Consulting, and Georgeson.
Bringing together Diligent’s leading governance, analytics and ESG solutions with Insightia’s vital intelligence across a variety of public company data will provide clients with even more meaningful insights to power their board and organizations’ governance practices. Clients will have access to a rich ecosystem of organizational risk assessments and data tools in areas spanning board composition, executive compensation, supply chain due diligence, and ESG standards and frameworks. Diligent will also pursue a range of potential solution integrations with Insightia, including adding activist investor alerts within its Boards application, enabling clients to better monitor susceptibility to activism.
Brian Stafford, CEO of Diligent, said: “From our regular interactions with board members, business leaders and investors, we understand that having access to the most comprehensive and relevant data facilitates better guidance and confident decision-making. That is why we are so pleased to bring onboard Insightia’s deep experience and market-leading intelligent analytics, particularly against the backdrop of a marketplace where shareholder engagement is rapidly evolving. Current and future clients can look forward to even more insights on the issues that matter most so that they can continue to build successful, equitable and sustainable organizations.”
Kerry Pogue, Co-Founder and CEO of Insightia, said: “We are excited to benefit from Diligent’s expertise and resources as a leading SaaS organization in this next phase of Insightia’s growth journey. Combining our capabilities with Diligent’s governance, analytics and ESG solutions is a compelling next step as we look to scale our offerings globally for the benefit of our clients. Both companies are incredibly complementary in terms of their strategy and culture, and our team looks forward to being part of Diligent and accelerating the reach of our mission.”
District Capital Partners served as the exclusive financial advisor, and Willkie Farr & Gallagher LLP served as the legal advisor to Diligent. Taylor Wessing served as the legal advisor to Insightia.
About Diligent Corporation
Diligent is the global leader in modern governance providing SaaS solutions across governance, risk, compliance and ESG to over 1 million users from over 25,000 customers around the world. Our innovative technology gives leaders a connected view of governance, risk, compliance and ESG across their organizations, sparking the insights they need to make better decisions and lead with purpose. Learn more at diligent.com.
About Insightia
Headquartered in London, Insightia was formed in 2020 through the merger of Activist Insight and Proxy Insight, who together have provided a variety of shareholder activism, shareholder voting, and corporate governance data to a global client base for the past decade. Insightia’s mission is to improve engagement, stewardship and corporate governance through the delivery of timely intelligence to key stakeholders and their advisors. Learn more at insightia.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220111005384/en/
Contact information
Media
Samuel Barber
Cognito
+1 917 246 2775
Samuel.Barber@cognitomedia.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
VerSprite Launches Fork and Knife: AI-Driven Threat Modeling and Adversarial Testing Built for the Speed of Modern Software27.6.2026 00:28:00 EEST | Press release
VerSprite, a global leader in risk-based threat modeling and the firm behind the PASTA (Process for Attack Simulation and Threat Analysis) methodology, today announced the general availability of Fork (www.forktm.com), a continuous application threat modeling platform, alongside Knife, an AI-led, human-on-the-loop adversarial testing platform for web applications and web API endpoints. Together, the two products operationalize a new model for product security—one where applications are securely designed, continuously modeled, and actively tested as part of the build process itself. The launch addresses a problem every security leader knows but few tools have solved: threat modeling is essential, never more so than in an AI-driven era, yet it has remained slow, manual, and anchored to frameworks designed for a different threat landscape. The problem: threat modeling matters more than ever—and most tools are stuck in 2005 For two decades, application threat modeling has leaned heavily on
Venture Global Announces Closing of $1.5 Billion Senior Secured Vessel Financing Facility26.6.2026 23:30:00 EEST | Press release
Venture Global, Inc. (NYSE: VG) announced today that its wholly-owned subsidiary, Venture Global Shipping Holdings, LLC (“VGSH”), has entered into a Credit and Guaranty Agreement providing for a senior secured term loan facility (the “Facility”) in an aggregate principal amount of up to $1,500,000,000. The Facility will mature on June 26, 2032. Deutsche Bank and ING acted as coordinating lead arrangers for the Facility. ING also serves as facility agent and security trustee. VGSH intends to use the net proceeds from the Facility for general corporate purposes, including to reimburse Venture Global LNG, Inc. for payments previously made by it or its affiliates in connection with the acquisition of nine LNG carriers, funding certain reserve accounts, and paying transaction fees and expenses. About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (“LNG”) with over 100 MTPA of capacity in production, construction, or development. Ven
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 21:00:00 EEST | Press release
Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solution – uses digital twin technology to identify vulnerable customers and recommend explainable next-best actions for fro
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom